



## Recent Advances in Cardiovascular Drug Discovery and Development

Guest Editors:

### **Prof. Dr. Grzegorz Grzešek**

Department of Cardiology and  
Clinical Pharmacology, Faculty of  
Health Sciences, Collegium  
Medicum in Bydgoszcz, Nicolaus  
Copernicus University, 75  
Ujejskiego St., 85-168 Bydgoszcz,  
Poland

### **Prof. Dr. Alicja Nowaczyk**

Department of Organic  
Chemistry, Faculty of Pharmacy,  
Collegium Medicum in  
Bydgoszcz, Nicolaus Copernicus  
University, 2 dr. A. Jurasza St., 85-  
094 Bydgoszcz, Poland

Deadline for manuscript  
submissions:

**closed (31 January 2024)**

### **Message from the Guest Editors**

Dear Colleagues,

The therapeutic management of cardiac diseases is changing rapidly. While at the end of the 20th century, mainly symptomatic therapies were dominant, in recent years activities aimed at modifying the metabolism of cells or influencing more and more interesting signalling pathways have become the attitude. As new discoveries are made, new options are introduced into routine clinical management.

At the same time, there are new challenges, for example, better options for patients treated for heart failure or completely new problems, such as the need to treat complications after COVID-19 infection.

In such a situation, a significant acceleration of the search for new indications for known drugs, and new more effective as-yet-unknown indications, new pathways, and modulating agents that may be beneficial in therapy. Thus, research activities begin with molecular chemistry and end with evaluation in randomized clinical trials.

Hence, the purpose of this Special Issue of *Molecules* is to gather knowledge and advancements including clinical, translational, and preclinical evaluations of active cardiovascular compounds.





an Open Access Journal by MDPI

## Editor-in-Chief

### Prof. Dr. Thomas J. Schmidt

Institute of Pharmaceutical  
Biology and Phytochemistry,  
University of Münster,  
Corrensstrasse 48, D-48149  
Münster, Germany

## Message from the Editor-in-Chief

As the premier open access journal dedicated to experimental organic chemistry, and now in its 25th year of publication, the papers published in *Molecules* span from classical synthetic methodology to natural product isolation and characterization, as well as physicochemical studies and the applications of these molecules as pharmaceuticals, catalysts and novel materials. Pushing the boundaries of the discipline, we invite papers on multidisciplinary topics bridging biochemistry, biophysics and materials science, as well as timely reviews and topical issues on cutting edge fields in all these areas.

## Author Benefits

**Open Access:** free for readers, with [article processing charges \(APC\)](#) paid by authors or their institutions.

**High Visibility:** indexed within [Scopus](#), [SCIE \(Web of Science\)](#), [PubMed](#), [MEDLINE](#), [PMC](#), [Reaxys](#), [CaPlus / SciFinder](#), [MarinLit](#), [AGRIS](#), and [other databases](#).

**Journal Rank:** JCR - Q2 (Chemistry, Multidisciplinary) / CiteScore - Q1 (Chemistry (miscellaneous))

## Contact Us

---

*Molecules* Editorial Office  
MDPI, Grosspeteranlage 5  
4052 Basel, Switzerland

Tel: +41 61 683 77 34  
[www.mdpi.com](http://www.mdpi.com)

[mdpi.com/journal/molecules](http://mdpi.com/journal/molecules)  
[molecules@mdpi.com](mailto:molecules@mdpi.com)  
[X@Molecules\\_MDPI](#)